Sign up to save your podcasts
Or
Share U.S. MedTech: Pure Global on FDA's New Real-World Data Rules
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
U.S. MedTech: Pure Global on FDA's New Real-World Data Rules
In the final days of 2025, the U.S. FDA unveiled a pivotal shift in policy, now allowing broader use of Real-World Data (RWD) in medical device submissions. This episode of MedTech Global Insights unpacks what this means for the industry, from startups to global enterprises. We explore the immense opportunities this presents for accelerating innovation and improving post-market surveillance.
This change moves beyond theory and presents a new, tangible pathway for market access. We discuss the significant challenges that come with this new frontier, including the critical issues of data quality, patient privacy, and the sophisticated analytical methods required to transform raw data into regulatory-grade evidence that can withstand FDA scrutiny.
**Case Study:** A U.S.-based startup has developed a groundbreaking AI-powered diagnostic software. Their biggest hurdle is the prohibitive cost and timeline of a traditional clinical trial. With the FDA's new guidance, they now see a path to leverage years of anonymized patient data from partner hospitals. However, they are struggling to validate the data's integrity and build a submission dossier that will meet the FDA's rigorous new standards for RWD.
**What You'll Learn (本期干货):**
1. What exactly qualifies as "Real-World Data" under the FDA's new guidance?
2. How can this policy change slash time-to-market for new devices?
3. What are the biggest risks and compliance traps when using RWD for a submission?
4. How will this impact the requirements for post-market surveillance activities?
5. Can RWD be used to expand the approved indications for an existing device?
6. What kind of data infrastructure do companies need to build to leverage this opportunity?
7. How does the new U.S. policy compare to the European Union's stance on RWD?
8. What are the key elements the FDA looks for in a RWD analysis plan?
Contact us at [email protected] or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.
View all episodes
By Ran ChenIn the final days of 2025, the U.S. FDA unveiled a pivotal shift in policy, now allowing broader use of Real-World Data (RWD) in medical device submissions. This episode of MedTech Global Insights unpacks what this means for the industry, from startups to global enterprises. We explore the immense opportunities this presents for accelerating innovation and improving post-market surveillance.
This change moves beyond theory and presents a new, tangible pathway for market access. We discuss the significant challenges that come with this new frontier, including the critical issues of data quality, patient privacy, and the sophisticated analytical methods required to transform raw data into regulatory-grade evidence that can withstand FDA scrutiny.
**Case Study:** A U.S.-based startup has developed a groundbreaking AI-powered diagnostic software. Their biggest hurdle is the prohibitive cost and timeline of a traditional clinical trial. With the FDA's new guidance, they now see a path to leverage years of anonymized patient data from partner hospitals. However, they are struggling to validate the data's integrity and build a submission dossier that will meet the FDA's rigorous new standards for RWD.
**What You'll Learn (本期干货):**
1. What exactly qualifies as "Real-World Data" under the FDA's new guidance?
2. How can this policy change slash time-to-market for new devices?
3. What are the biggest risks and compliance traps when using RWD for a submission?
4. How will this impact the requirements for post-market surveillance activities?
5. Can RWD be used to expand the approved indications for an existing device?
6. What kind of data infrastructure do companies need to build to leverage this opportunity?
7. How does the new U.S. policy compare to the European Union's stance on RWD?
8. What are the key elements the FDA looks for in a RWD analysis plan?
Contact us at [email protected] or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.